Our Technology

When I'm a doctor, precision healthcare will exist

Diagnosing the right treatment at the right time in the way that has the lowest impact on a persons life. This is our goal for precision healthcare.

Protein-informed decisions

Rather than the most advanced healthcare decisions being based on incomplete information about DNA, RNA and individual proteins, with the right technology, decisions can be based on a deep understanding of every protein and every protein interaction in any sample.

From Genes to Proteins

The study of genes (Genomics) has seen a transformation in our understanding of human biology. Proteins are produced from genes and these drive life in every living organism. The study of proteins (Proteomics), enables us to understand the normal processes that contribute to our daily wellness, as well as those that lead to disease.

We are building a data-set that contains more comprehensive and accurate information about proteins than ever before. Their structure, behaviour, how they interact with other molecules within the body, and how they interact with drug therapies. This data-set will provide an accurate and reliable registry of proteins and their actions, empowering us to know exactly what is happening in our bodies, and what is likely to happen.

We envision a world where accurate information about proteins helps all of us to make better, more informed decisions about how we diagnose disease, develop treatments and maintain a better state of health.

Proteins are produced from your DNA. The shape, structure, actions and interactions of proteins are the mechanisms that maintain life. Fluidic Analytics recognise the potential impact of proteins on the future of human healthcare, therefore, that’s our focus.

Studying real proteins in solution in a near native state eliminates guesswork and enables us to make accurate predictions and obtain accurate results. Our easy-to-use technology makes it possible to observe, characterise and measure proteins and their interactions in solution with no foreign surfaces or matrices affecting results. Superior technology advances understanding, opens new possibilities and avoids failure of research or treatments further down the line.

The potential is vast

Fluidic Analytics’ technology offers new capabilities in biological research. Our technology was developed at the University of Cambridge where we have created a more accurate and reliable way to characterise and measure proteins, their actions and their interactions.

Fluidic Analytics’ technology harnesses steady-state laminar-flow microfluidics in a multidimensional fashion using biophysical and biochemical separation and detection modules. This in-solution platform is scalable from single protein to proteomic-level interaction analysis making it extremely versatile. Ultimately, Fluidic Analytics aims are to make a significant contribution towards making healthcare precise.

Fluidic info graphic
The high quality of our peer reviews emphasise the high quality of our work

1.      Yates et al. Latent analysis of unmodified biomolecules and their complexes in solution with attomole detection sensitivity. Nature Chemistry 2015, 7, 802-809 (summary)
2.      Arosio et al. Microfluidic diffusion analysis of the sizes and interactions of proteins under native solution conditions. ACS Nano 2016, 10, 333-341 (summary)
3.      Arosio et al. Microfluidic diffusion viscometer for rapid analysis of complex solutions. Anal. Chem 2016, 88, 488-3493 (summary)
4.      Herling et al. A Microfluidic Platform for Real-Time Detection and Quantification of Protein-Ligand Interactions. Biophysical Journal 2016, 110, 1957-1966 (summary)
5.      Zhang et al. Protein Aggregate-Ligand Binding Assays Based on Microfluidic Diffusional Separation. ChemBioChem 2016, 17, 1920-1924 (summary)
6.      Lapinska et al. Gradient-free determination of isoelectric points of proteins on chip. Phys Chem Chem Phys 2017, 19, 23060-23067 (summary)
7.      Saar et al. On-chip label-free protein analysis with downstream electrodes for direct removal of electrolysis products. Lab Chip 2018, 18, 162-170 (summary)
8.      Wright et al. Cooperative Assembly of Hsp70 Subdomain Clusters. Biochemistry 2018, 57, 3641-3649 (summary)
9.      Falke et al. α-Synuclein-derived lipoparticles in the study of α-Synuclein amyloid fibril formation. Chemistry and Physics of Lipids 2019, 220, 57-65 (summary)
10.    Scheidt et al. Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates. Science Advances 2019, 5, eaau3112 (summary)
11.   Gang et al. A microfluidic diffusion platform for characterizing the size of lipid vesicles and the thermodynamics of protein-lipid interactions. Anal. Chem 2018, 90, 3284-3290 (summary)
12.   Macikova et al. Putative interaction site for membrane phospholipids controls activation of TRPA1 channel at physiological membrane potentials. The FEBS Journal 2019, 14931 (summary)
13.   Wright et al. Analysis of αB-crystallin polydispersity in solution through native microfluidic electrophoresis. Analyst 2019, 144, 4413-4424 (summary)

14.   Hoppen and Growth Novel insights into the transfer routes of the essential copper cofactor to the ethylene plant hormone receptor family, Taylor & Francis 2020, 1716512 (publication)